Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 44

Sort by

Sort Order Select

Journal Articles

Toxicity profile of epcoritamab and glofitamab in aggressive B-cell lymphoma: A real-world analysis of CRS and icans in a single-center cohort

Yumeng Zhang, Daniel DeAvila, Fatima Tuz Zahra, Bijal Shah, Sameh Gaballa, Celeste Bello, Hayder Saeed, Leidy Isenalumhe, Lubomir Sokol, Michael Jain, Zachary Thompson, Javier Pinilla-Ibarz, Julio Chavez

Blood (2025) 146 (Supplement 1): 8017.

https://doi.org/10.1182/blood-2025-8017

Published: 2025

Journal Articles

Frontline chemotherapy for CD30+ non-ALCL peripheral T-cell lymphoma a multi-center retrospective analysis

Blood (2025) 146 (Supplement 1): 3641.

https://doi.org/10.1182/blood-2025-3641

Published: 2025

Journal Articles

Real-world efficacy outcomes of epcoritamab and glofitamab in Relapsed/Refractory aggressive B-cell lymphoma: A single-center cohort emphasizing trial-ineligible populations

Yumeng Zhang, Fatima Tuz Zahra, Daniel DeAvila, Bijal Shah, Sameh Gaballa, Celeste Bello, Hayder Saeed, Abu-Sayeef Mirza, Leidy Isenalumhe, Omar Alexis Castaneda Puglianini, Aleksandr Lazaryan, Lubomir Sokol, Frederick Locke, Michael Jain, Zachary Thompson, Javier Pinilla-Ibarz, Julio Chavez

Blood (2025) 146 (Supplement 1): 2767.

https://doi.org/10.1182/blood-2025-2767

Published: 2025

Journal Articles

Rare cancer, rare survivors: A 20-year single-center review of adult T-cell lymphoma/leukemia treatment outcomes

Yumeng Zhang, Hayder Saeed, Amin Azem, Jose Sandoval-Sus, Fatima Tuz Zahra, Kavita Ghia, Abu-Sayeef Mirza, Bijal Shah, Celeste Bello, Javier Pinilla-Ibarz, Ling Zhang, Lubomir Sokol

Blood (2025) 146 (Supplement 1): 7161.

https://doi.org/10.1182/blood-2025-7161

Published: 2025

Journal Articles

Outcomes of CD20xCD3 bispecific antibody therapy as holding or bridging therapy prior to chimeric antigen receptor T-cell infusion in aggressive B-cell lymphomas

Fatima Tuz Zahra, Yumeng Zhang, Sameh Gaballa, Celeste Bello, Samuel Reynolds, Leidy Isenalumhe, Omar Alexis Castaneda Puglianini, Hayder Saeed, Aleksandr Lazaryan, Abu-Sayeef Mirza, Lubomir Sokol, Bijal Shah, Frederick Locke, Michael Jain, Javier Pinilla-Ibarz, Julio Chavez

Blood (2025) 146 (Supplement 1): 4555.

https://doi.org/10.1182/blood-2025-4555

Published: 2025

Journal Articles

Real-world survival outcomes following allogeneic hematopoietic cell transplantation in peripheral T-cell lymphomas: A Florida multi-institutional cohort study

Blood (2025) 146 (Supplement 1): 4537.

https://doi.org/10.1182/blood-2025-4537

Published: 2025

Journal Articles

S2207: Randomized Phase II Study of the Addition of Targeted Agents to Tafasitamab-Lenalidomide in Transplant Ineligible Patients with Relapsed/Refractory LBCL

Jennifer E. Amengual, Hongli Li, Patrick M. Reagan, Tareq Al Baghdadi, Hayder Saeed, Joseph M Unger, Alexey Danilov, Michael Leblanc, Jonathan W. Friedberg, Sonali M. Smith

Blood (2024) 144 (Supplement 1): 3123.2.

https://doi.org/10.1182/blood-2024-199784

Published: 2024

Journal Articles

Asparaginase Treatment Patterns, Toxicity, and Outcomes Among Patients with Extranodal NK/T-Cell Lymphoma: A North American Multicenter Retrospective Cohort Study

Blood (2024) 144 (Supplement 1): 1690.

https://doi.org/10.1182/blood-2024-211424

Published: 2024

Journal Articles

The Real-World Safety and Tolerability of Pirtobrutinib Among Patients with B Cell Lymphomas; A Single Center Experience

Mohammad Ammad Ud Din, Katherine Tobon, Julio C. Chavez, Lisa Nodzon, Hayder Saeed, Sameh Gaballa, Ning Dong, Leidy Lismeris Isenalumhe, Celeste M. Bello, Ariel Grajales-Cruz, Kenneth H. Shain, Lubomir Sokol, Bijal D Shah, Javier Pinilla-Ibarz

Blood (2024) 144 (Supplement 1): 6778.

https://doi.org/10.1182/blood-2024-208769

Published: 2024

Journal Articles

Real World Experience with Sequential Brentuximab Vedotin Plus AVD Chemotherapy As Frontline Therapy for Older Patients with Classical Hodgkin Lymphoma: A Multicenter Retrospective Study

Ariel Perez Perez, Nayef Abdel-Razeq, Tiba Al Sagheer, George Nahas, Jose Sandoval-Sus, Manny Alfonso, Carlos Silva, Syeda Saba Kareem, Katherine Tobon, Allison C. Rosenthal, Stephen M. Ansell, Yuliya PL Linhares, Muhamad Alhaj Moustafa, Hayder Saeed

Blood (2024) 144 (Supplement 1): 1672.

https://doi.org/10.1182/blood-2024-208781

Published: 2024

Journal Articles

A Phase I Study of Duvelisib in Combination with Oral Azacitidine (BMS-986345) in Mature T Cell Lymphoma

Hayder Saeed, Melanie Mediavilla Varela, Eva Sahakian, Mahrukh Naqvi, Qiangxing Mo, Ling Zhang, Rikesh Makanji, Yumeng Zhang, Ning Dong, Leidy Lismeris Isenalumhe, Sameh Gaballa, Julio C. Chavez, Bijal D Shah, Celeste M. Bello, Lubomir Sokol, Javier Pinilla-Ibarz

Blood (2024) 144 (Supplement 1): 3065.

https://doi.org/10.1182/blood-2024-205173

Published: 2024

Journal Articles

Treatment Patterns and Outcomes for Patients with Classic Hodgkin Lymphoma (cHL) and Cardiomyopathy with Low Ejection Fraction (EF): Real-World Evidence (RWE) from 16 US Academic Centers

Blood (2023) 142 (Supplement 1): 382.

https://doi.org/10.1182/blood-2023-182389

Published: 2023

Journal Articles

Allogeneic Stem Cell Transplant and CD30 Directed CART Cell Therapies Are Associated with Improved Survival in Classical Hodgkin Lymphoma Refractory or Intolerant to Brentuximab Vedotin and Anti-PD-1 Therapy: Real World Analysis from 14 U.S. Academic Centers

Blood (2023) 142 (Supplement 1): 900.

https://doi.org/10.1182/blood-2023-182385

Published: 2023

Journal Articles

A Retrospective Study on Outcomes of Secondary CNS Lymphoma: Pattern of Relapse, Prognostic Factors, and Role of Consolidation Therapy

Aditi Saha, Junmin Whiting, Mohammad Ammad-ud-din, Cole Powell, Kristen Flores, Felix Sanjay, Humaira Sarfraz, Khushali Jhaveri, Michael V. Jaglal, Katherine Tobon, Hayder Saeed, Celeste M. Bello, Bijal D. Shah, Leidy Lismeris Isenalumhe, Javier Pinilla-Ibarz, Lubomir Sokol, Julio C Chavez, Ning Dong

Blood (2023) 142 (Supplement 1): 1750.

https://doi.org/10.1182/blood-2023-188211

Published: 2023

Journal Articles

Outcomes in Patients with Classical Hodgkin Lymphoma Refractory or Intolerant to Brentuximab Vedotin and Anti-PD-1 Therapy: Real World Analysis from 14 U.S. Academic Centers

Blood (2023) 142 (Supplement 1): 3061.

https://doi.org/10.1182/blood-2023-181056

Published: 2023

Journal Articles

Clinical Characteristics, Treatment Strategies, and Outcomes for CLL Patients with BTK Mutation; A Single Center Study

Mohammad Ammad Ud Din, Todd C Knepper, Julio C. Chavez, Lisa Nodzon, Hayder Saeed, Sameh Gaballa, Lubomir Sokol, Ning Dong, Leidy Lismeris Isenalumhe, Celeste M. Bello, Bijal D. Shah, Javier Pinilla-Ibarz

Blood (2023) 142 (Supplement 1): 1911.

https://doi.org/10.1182/blood-2023-179658

Published: 2023

Journal Articles

Open-Label, Randomized, Phase 3 Study of Coformulated Favezelimab and Pembrolizumab Versus Chemotherapy in Patients with Relapsed or Refractory Classical Hodgkin Lymphoma Refractory to Anti-PD-1 Therapy: Keyform-008

David Lavie, John Timmerman, Ramón García-Sanz, Won Seog Kim, Tae Min Kim, Abraham Avigdor, Daan Dierickx, Deepa Jagadeesh, Daniel L. Molin, Muhit Ozcan, Omur Gokmen Sevindik, Hayder Saeed, Yulia Sidi, Pallavi Pillai, Patricia Marinello, Alex F. Herrera

Blood (2023) 142 (Supplement 1): 3082.

https://doi.org/10.1182/blood-2023-182119

Published: 2023

Journal Articles

B-Cell Maturation Antigen (BCMA) Expression and Clinical Features of Plasmablastic Lymphoma (PBL)

Ning Dong, Hailing Zhang, Jinming Song, Jamila Mammadova, Bijal D. Shah, Hayder Saeed, Ariel F. Grajales-Cruz, Leidy Lismeris Isenalumhe, Sameh Gaballa, Celeste M. Bello, Lubomir Sokol, Javier Pinilla-Ibarz, Julio C Chavez

Blood (2023) 142 (Supplement 1): 3138.

https://doi.org/10.1182/blood-2023-184779

Published: 2023

Journal Articles

Comparing Survival Outcomes of Autologous and Allogeneic Hematopoietic Cell Transplantation in Patients with Relapsed/Refractory Nodal Peripheral T-Cell Lymphoma

Yumeng Zhang, Jennifer Eatrides, Ashley Rose, Ling Zhang, Farhad Khimani, Aleksandr Lazaryan, Bijal D. Shah, Hayder Saeed, Michael D. Jain, Hien D. Liu, Frederick L. Locke, Javier Pinilla Ibarz, Jongphil Kim, Mohamed A. Kharfan-Dabaja, Ernesto Ayala, Lubomir Sokol, Taiga Nishihori

Blood (2022) 140 (Supplement 1): 10634–10636.

https://doi.org/10.1182/blood-2022-169200

Published: 2022

Journal Articles

Safety, Tolerability, PK/PD and Preliminary Efficacy of NKTR-255, a Novel IL-15 Receptor Agonist, in Patients with Relapsed/Refractory Hematologic Malignancies

Blood (2022) 140 (Supplement 1): 10357–10359.

https://doi.org/10.1182/blood-2022-162539

Published: 2022

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

Toxicity profile of epcoritamab and glofitamab in aggressive B-cell lymphoma: A real-world analysis of CRS and icans in a single-center cohort

Frontline chemotherapy for CD30+ non-ALCL peripheral T-cell lymphoma a multi-center retrospective analysis

Real-world efficacy outcomes of epcoritamab and glofitamab in Relapsed/Refractory aggressive B-cell lymphoma: A single-center cohort emphasizing trial-ineligible populations

Rare cancer, rare survivors: A 20-year single-center review of adult T-cell lymphoma/leukemia treatment outcomes

Outcomes of CD20xCD3 bispecific antibody therapy as holding or bridging therapy prior to chimeric antigen receptor T-cell infusion in aggressive B-cell lymphomas

Real-world survival outcomes following allogeneic hematopoietic cell transplantation in peripheral T-cell lymphomas: A Florida multi-institutional cohort study

S2207: Randomized Phase II Study of the Addition of Targeted Agents to Tafasitamab-Lenalidomide in Transplant Ineligible Patients with Relapsed/Refractory LBCL

Asparaginase Treatment Patterns, Toxicity, and Outcomes Among Patients with Extranodal NK/T-Cell Lymphoma: A North American Multicenter Retrospective Cohort Study

The Real-World Safety and Tolerability of Pirtobrutinib Among Patients with B Cell Lymphomas; A Single Center Experience

Real World Experience with Sequential Brentuximab Vedotin Plus AVD Chemotherapy As Frontline Therapy for Older Patients with Classical Hodgkin Lymphoma: A Multicenter Retrospective Study

A Phase I Study of Duvelisib in Combination with Oral Azacitidine (BMS-986345) in Mature T Cell Lymphoma

Treatment Patterns and Outcomes for Patients with Classic Hodgkin Lymphoma (cHL) and Cardiomyopathy with Low Ejection Fraction (EF): Real-World Evidence (RWE) from 16 US Academic Centers

Allogeneic Stem Cell Transplant and CD30 Directed CART Cell Therapies Are Associated with Improved Survival in Classical Hodgkin Lymphoma Refractory or Intolerant to Brentuximab Vedotin and Anti-PD-1 Therapy: Real World Analysis from 14 U.S. Academic Centers

A Retrospective Study on Outcomes of Secondary CNS Lymphoma: Pattern of Relapse, Prognostic Factors, and Role of Consolidation Therapy

Outcomes in Patients with Classical Hodgkin Lymphoma Refractory or Intolerant to Brentuximab Vedotin and Anti-PD-1 Therapy: Real World Analysis from 14 U.S. Academic Centers

Clinical Characteristics, Treatment Strategies, and Outcomes for CLL Patients with BTK Mutation; A Single Center Study

Open-Label, Randomized, Phase 3 Study of Coformulated Favezelimab and Pembrolizumab Versus Chemotherapy in Patients with Relapsed or Refractory Classical Hodgkin Lymphoma Refractory to Anti-PD-1 Therapy: Keyform-008

B-Cell Maturation Antigen (BCMA) Expression and Clinical Features of Plasmablastic Lymphoma (PBL)

Comparing Survival Outcomes of Autologous and Allogeneic Hematopoietic Cell Transplantation in Patients with Relapsed/Refractory Nodal Peripheral T-Cell Lymphoma

Safety, Tolerability, PK/PD and Preliminary Efficacy of NKTR-255, a Novel IL-15 Receptor Agonist, in Patients with Relapsed/Refractory Hematologic Malignancies

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only